SHARE is an easy-to-search, real-time repository of HIV-related systematic reviews. Whether you’re a researcher, community member, healthcare provider or policymaker, SHARE provides a ‘one-stop shop’ for HIV-related information that has been published through a systematic review.

INTRODUCTION: Economic evaluations of HIV pre-exposure prophylaxis (PrEP) and associated implementation strategies guide evidence-based policies, programmes and resource allocation. Since 2015, there has been an evolution in PrEP modalities, implementation...

Rationale: Obstructive lung disease (OLD) pathogenesis includes inhalational (e.g., smoking) and noninhalational mechanisms (e.g., infections). Human immunodeficiency virus (HIV) has been suggested as a novel OLD risk factor. Substantial data...

Objective This systematic review and meta-analysis aims to characterize the distribution of HIV-1 viral tropism at diagnosis among people living with HIV (PLWH) and examine its association with baseline CD4+ T...

Integrase strand transfer inhibitors (INSTIs) have emerged as cornerstone agents in global antiretroviral therapy, though growing drug resistance presents clinical challenges. Conventional Sanger sequencing may underestimate the burden of low-frequency...

INTRODUCTION: While economic vulnerability is an established driver of health disparities, the relationships between HIV and wealth, income, and economic inequality have been less consistently established. We conducted a systematic...

BACKGROUND: An overview of existing research on HIV testing among transgender and other gender-diverse (TGD) populations in the United States, critical for developing effective future interventions and research, is missing....

Introduction Randomized controlled trial evidence suggests that long‐acting injectable (LA‐I) cabotegravir and rilpivirine (CAB+RPV) has similar virological failure (VF) rates to daily oral therapy, but clinical practice evidence is lacking....

The HIV epidemic in sub-Saharan Africa (SSA) continues to spread primarily through heterosexual contact, and in many countries, heterosexual men continue to exhibit a high HIV incidence with resultant morbidity...

Background: Dolutegravir (DTG) + lamivudine (3TC) has demonstrated efficacy and safety in phase 3 clinical trials; however, most published data are from people with HIV-1 in North America and Europe. Methods: To...

BACKGROUND: The COVID-19 pandemic caused significant disruptions to global healthcare systems, including essential services along the HIV care continuum (HCC). While several studies have examined these impacts in specific countries...

AIM: To systematically integrate the psychosocial experiences and coping mechanisms of AIDS patients after the disease, and to understand their true feelings, in order to provide a basis for better...

Background Antiretroviral (ARV) exposure influences the early-life gut microbiota in regions with high human immunodeficiency virus (HIV) burdens. Understanding how ARV drugs affect the infant gut microbiota is important for...